GSDIa Disease Monitoring Program
Latest Information Update: 28 Nov 2024
Price :
$35 *
At a glance
- Drugs Pariglasgene-brecaparvovec (Primary)
- Indications Glycogen storage disease type I
- Focus Adverse reactions
- Sponsors Ultragenyx Pharmaceutical
- 25 Nov 2024 Status changed from not yet recruiting to recruiting.
- 15 Oct 2024 New trial record